Differences in kinetics of tacrolimus concentration after letermovir discontinuation by type of concomitant azole antifungal
暂无分享,去创建一个
H. Hashimoto | T. Fukuda | Y. Inamoto | Toshihisa Nakashima | Takashi Tanaka | J. Aoki | T. Furukawa | A. Ito | Sung-Won Kim
[1] H. Hashimoto,et al. Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation , 2021, International Journal of Hematology.
[2] J. McCrea,et al. Assessment of Pharmacokinetic Interaction Between Letermovir and Fluconazole in Healthy Participants , 2020, Clinical pharmacology in drug development.
[3] K. Ikegame,et al. Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study , 2020, International journal of medical sciences.
[4] W. Kraft,et al. Pharmacokinetic Drug‐Drug Interactions Between Letermovir and the Immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil , 2019, Journal of clinical pharmacology.
[5] Karsten Menzel,et al. PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling , 2018, Clinical pharmacology and therapeutics.
[6] H. Stobernack,et al. Pharmacokinetics and Safety of Letermovir Coadministered With Cyclosporine A or Tacrolimus in Healthy Subjects , 2018, Clinical pharmacology in drug development.
[7] A. Groll,et al. Drug‐drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4 , 2017, Transplant infectious disease : an official journal of the Transplantation Society.
[8] Esther S. Kim,et al. Letermovir: First Global Approval , 2017, Drugs.
[9] Y. Kanda,et al. Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.
[10] Thomas M Polasek,et al. Perpetrators of pharmacokinetic drug-drug interactions arising from altered cytochrome P450 activity: a criteria-based assessment. , 2011, British journal of clinical pharmacology.
[11] M. Boeckh,et al. How we treat cytomegalovirus in hematopoietic cell transplant recipients. , 2009, Blood.
[12] H. K. Cho,et al. Influence of fluconazole on the pharmacokinetics of omeprazole in healthy volunteers. , 2002, Biopharmaceutics & drug disposition.